

Elizabeth Henry

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9921541/publications.pdf>

Version: 2024-02-01

25
papers

118
citations

1683934

5
h-index

1372474

10
g-index

26
all docs

26
docs citations

26
times ranked

173
citing authors

#	ARTICLE	IF	CITATIONS
1	Forming the Hematology-Oncology Collaborative Videoconferencing (CO-VID) Learning Initiative: Experiential Lessons Learned From a Novel Trainee-Led Multidisciplinary Virtual Learning Platform. JCO Oncology Practice, 2022, 18, e36-e46.	1.4	6
2	Impact of COVID-19 on Hematology-Oncology Fellowship Programs: A Quantitative and Qualitative Survey Assessment of Fellowship Program Directors. JCO Oncology Practice, 2022, 18, e551-e563.	1.4	6
3	Impact of COVID-19 on Hematology-Oncology Trainees: A Quantitative and Qualitative Assessment. JCO Oncology Practice, 2022, 18, e586-e599.	1.4	9
4	Social Media and Professional Development for Oncology Professionals. JCO Oncology Practice, 2022, 18, 566-571.	1.4	7
5	Making National Cancer Instituteâ€œDesignated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational Study. JMIR Cancer, 2022, 8, e33859.	0.9	0
6	Impact of social media on the emotional health and burnout of pediatric and adult oncology professionals: A SWOG and COG survey.. Journal of Clinical Oncology, 2022, 40, 11013-11013.	0.8	0
7	Veterans affairs seamless phase II/III randomized trial of standard systemic therapy with or without PET-directed local therapy for oligorecurrent prostate cancer (VA STARPORT).. Journal of Clinical Oncology, 2022, 40, TPS5112-TPS5112.	0.8	0
8	Social Media and the Quest for Equity and Diversity in Oncology: On Safe Spaces and the Concept of the Public Physician. JCO Oncology Practice, 2022, 18, 572-577.	1.4	1
9	Treatment of Metastatic Carcinoma of an Unknown Primary to the Heart with Checkpoint Inhibitor Therapy. Oncology Research and Treatment, 2021, 44, 190-195.	0.8	0
10	Inhibition of Histone Deacetylase (HDAC) Enhances Checkpoint Blockade Efficacy by Rendering Bladder Cancer Cells Visible for T Cell-Mediated Destruction. Frontiers in Oncology, 2020, 10, 699.	1.3	26
11	Feasibility of developing a Twitter journal club for hematology/oncology education.. Journal of Clinical Oncology, 2020, 38, 11004-11004.	0.8	2
12	Study EV-103: New randomized cohort testing enfortumab vedotin as monotherapy or in combination with pembrolizumab in locally advanced or metastatic urothelial cancer.. Journal of Clinical Oncology, 2020, 38, TPS5092-TPS5092.	0.8	4
13	<i>Measuring the Impact of COVID-19 on Hematology-Oncology Trainees: A Quantitative and Qualitative Assessment</i>. Blood, 2020, 136, 20-21.	0.6	3
14	The Impact of COVID-19 on Hematology-Oncology Fellowship Programs: Program Director Perspectives. Blood, 2020, 136, 24-25.	0.6	0
15	Emerging Role of Fluciclovine and Other Next Generation PET Imaging Agents in Prostate Cancer Management. Current Radiology Reports, 2019, 7, 1.	0.4	0
16	The outcome and toxicity profile of checkpoint inhibitor immunotherapy subsequent to high-dose IL-2 in the treatment of metastatic melanoma and renal cell carcinoma.. Journal of Clinical Oncology, 2019, 37, 14-14.	0.8	0
17	Concurrent chemotherapy is associated with improved survival in elderly patients with bladder cancer undergoing radiotherapy. Cancer, 2017, 123, 3524-3531.	2.0	28
18	Association of treatment facility case volume with survival in patients undergoing radiotherapy/chemoradiotherapy for muscle-invasive bladder cancer: An analysis of the National Cancer Database.. Journal of Clinical Oncology, 2017, 35, 295-295.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Delivering Coordinated Cancer Care by Building Transactive Memory in a Team of Teams. Journal of Oncology Practice, 2016, 12, 992-999.	2.5	10
20	Experience with IL-2 in metastatic renal cell carcinoma after treatment with one or more targeted therapies.. Journal of Clinical Oncology, 2016, 34, 622-622.	0.8	0
21	Efficacy and tolerability of high dose interleukin-2 (HD IL-2) after disease progression on targeted therapy (TT) for metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2016, 34, e16064-e16064.	0.8	0
22	Effect of concurrent chemotherapy on overall survival in elderly bladder cancer patients undergoing radiotherapy: A population-based analysis.. Journal of Clinical Oncology, 2016, 34, e16000-e16000.	0.8	0
23	Self-reported memory problems in adult-onset cancer survivors: effects of cardiovascular disease and insomnia. Sleep Medicine, 2015, 16, 845-849.	0.8	16
24	Prevalence of atypical urine cytology in patients treated with gemcitabine-cisplatin (GC) for urothelial carcinoma (UC).. Journal of Clinical Oncology, 2015, 33, 363-363.	0.8	0
25	Risk factors for complicated grief (CG) and utilization of a hospice bereavement program.. Journal of Clinical Oncology, 2012, 30, e19588-e19588.	0.8	0